stonks4u
Log inSign up free
INVO logo

INVO INVO Bioscience, Inc.

NASDAQ Capital Market · Medical - Devices · Healthcare

$0.83
-0.02 (-2.00%)

INVO Bioscience, Inc. is a globally operating, commercial-phase enterprise focused on fertility, offering advanced solutions in assisted reproductive technology. Their leading product is the INVOcell, an innovative medical device engineered to allow fertilization and the initial development of embryos to naturally occur inside the woman's body. The company, headquartered in Sarasota, Florida, bega…

Market Cap: $3.25Minvofertility.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$0.82 – $0.88
52-Week Range
$0.63 – $3.50
Volume
$124.0K
Market Cap
$3.25M
50-Day Avg
$0.77
200-Day Avg
$0.90
Prev Close
$0.85
Open
$0.86

Valuation & Ratios

P/E Ratio
-0.00
EPS
$-214.64
P/B Ratio
0.01
P/S Ratio
0.01
Debt/Equity
0.50
Current Ratio
0.27
Dividend Yield
+755.9%
Gross Margin
+37.4%

Returns & Efficiency

Return on Equity
-347.9%
Return on Assets
-124.3%
FCF Yield
-7378.1%
EV/EBITDA
-0.06

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$6.84B$-25.13B$-214.64
2023$3.02M$-8.03M$-5.13
2022$822.2K$-10.89M$-17.97
2021$4.16M$-6.65M$-12.52
2020$1.04M$-8.35M$-30.41

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

0of 3 quarters beat consensus

Typical surprise -342.9% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 14$-0.62 vs $-0.14miss
  • Wed, May 15$-0.42 vs $-0.16miss
  • Tue, Apr 16$-4.60 vs $-0.87miss

Estimates and results for INVO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by INVO officers and directors.

Bought
$961k

25 trades

Sold
—

0 trades

  • Shum Stevebought
    Chief Executive Officer·58,885 @ $0.95·$56k·Jun 1, 2022·filing
  • Szot Matthew Kbought
    director:·14,474 @ $0.95·$14k·Jun 1, 2022·filing
  • Ryan Barbarabought
    director:·10,526 @ $0.95·$10k·Jun 1, 2022·filing
  • Davis Trent Dbought
    director:·11,184 @ $0.95·$11k·Jun 1, 2022·filing
  • Segal Jeffreybought
    director:·9,211 @ $0.95·$9k·Jun 1, 2022·filing
  • Campbell Michael Jos.bought
    Chief Operating Officer·10,526 @ $0.95·$10k·Jun 1, 2022·filing
  • Goren Andreabought
    Chief Financial Officer·52,632 @ $0.95·$50k·Jun 1, 2022·filing
  • Messina Rebeccabought
    director:·9,868 @ $0.95·$9k·Jun 1, 2022·filing

75 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

INVOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Neutral

    INVO Fertility Reports Second Quarter 2026 Results Highlighting Revenue Growth and Clinic Platform Profitability Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Compan…

    View source ↗